Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sven Rohmann, CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, Q3 2020
“It is a great pleasure to join Immunicum at this exciting stage of its corporate development and with the clinical progress the Company has achieved with ilixadencel, our off-the-shelf immune primer. Based on the encouraging clinical proof-of-concept through anti-tumor response and indications of survival benefits provided by the MERECA study as well as the growing body of clinical and pre-clinical data, we remain convinced of ilixadencel’s ability to enable more durable and stronger anti-tumor responses in combination with standard treatment regimens, and its potential to transform modern cancer immunotherapy.”– Sven Rohmann, CEO
To read the full report, please click here
Investor Downloads
